Vivos Therapeutics Inc (VVOS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vivos Therapeutics Inc (VVOS) has a cash flow conversion efficiency ratio of 4.743x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.01 Million) by net assets ($-1.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vivos Therapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Vivos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Vivos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vivos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vivos Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lupaka Gold Corp.
V:LPK
|
0.173x |
|
Diamond Estates Wines & Spirits Inc
V:DWS
|
-0.017x |
|
International Graphite Ltd
AU:IG6
|
-0.184x |
|
Perrot Duval Holding SA
SW:PEDU
|
0.023x |
|
Lions Bay Capital Inc
V:LBI
|
-0.152x |
|
Meihua International Medical Technologies Co. Ltd.
NASDAQ:MHUAF
|
0.055x |
|
Advanced Blockchain AG
XETRA:BWQ
|
0.011x |
|
Ajooni Biotech Limited
NSE:AJOONI
|
0.149x |
Annual Cash Flow Conversion Efficiency for Vivos Therapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Vivos Therapeutics Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see Vivos Therapeutics Inc (VVOS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.55 Million | $-15.26 Million | 9.847x | +717.16% |
| 2024-12-31 | $7.95 Million | $-12.69 Million | -1.596x | +94.51% |
| 2023-12-31 | $411.00K | $-11.95 Million | -29.066x | -612.43% |
| 2022-12-31 | $4.80 Million | $-19.59 Million | -4.080x | -562.18% |
| 2021-12-31 | $25.54 Million | $-15.73 Million | -0.616x | -83.50% |
| 2020-12-31 | $16.92 Million | $-5.68 Million | -0.336x | -118.50% |
| 2019-12-31 | $-2.94 Million | $-5.34 Million | 1.815x | +264.83% |
| 2018-12-31 | $4.83 Million | $-5.31 Million | -1.101x | -- |
About Vivos Therapeutics Inc
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnorma… Read more